XXXX following @entity205 therapy.

@entity1 @entity2826 @entity7617 @entity5 @entity1489 @entity8703 @entity205 @entity1358 @entity1893
Malignancies developed in 141 organ transplant recipients treated with @entity205 . The @entity5 showed important differences from those seen following @entity7617 ( @entity7617 ). They appeared an average of 20 months after @entity205 and 60 months after @entity7617 . @entity1893 ( @entity1893 ) were the most common @entity5 , being 41% compared with 12% in @entity7617 @entity1 . They appeared an average of 11 months after transplantation compared with an average of 42 months after @entity7617 . Unlike @entity7617 @entity1 they more often involved lymph nodes, more frequently involved the small intestine, rarely involved the brain, and were more likely to regress after reduction of immunosuppressive therapy. @entity1489 (15% of @entity5 ) were much less common than in @entity7617 @entity1 (40%). @entity2826 were more common (8% vs. 3%). In this small series there was a surprising @entity8703 and @entity1358 . Only 8 @entity1 (6%) were treated with @entity205 exclusively. The @entity5 probably are not specific to @entity205 therapy but appear to be a complication of immunosuppression per se.
